You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.



Clinical Quiz: Are You Ready for Hemophilia Gene Therapy?

  • Authors: Steven W. Pipe, MD
  • CME / ABIM MOC Released: 11/3/2022
  • Valid for credit through: 11/3/2023, 11:59 PM EST
Start Activity

Target Audience and Goal Statement

This activity is intended for hematologist/oncologists, pediatricians, primary care physicians, and other members of multidisciplinary teams who care for individuals with hemophilia.

The goal of this activity is for learners to assess their understanding of steps to integrate gene therapy for hemophilia into the multidisciplinary care model.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical data on gene therapy for treatment of hemophilia
  • Self-assess learning needs related to
    • Implementing gene therapy programs for patients with hemophilia


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Steven W. Pipe, MD

    Professor of Pediatrics and Pathology
    Pediatric Medical Director
    Hemophilia and Coagulation Disorders Program
    Director, Special Coagulation Laboratory
    University of Michigan
    Ann Arbor, Michigan


    Steven W. Pipe, MD, has the following relevant financial relationships:
    Consultant or advisor for: ApcinteX; ASC Therapeutics Inc.; Bayer; BioMarin Pharmaceutical Inc.; Catalyst Biosciences; CSL Behring; GeneVentiv Therapeutics Inc.; HEMA Biologics; Freeline Therapeutics; LFB; Novo Nordisk; Pfizer; Regeneron Pharmaceuticals/Intellia; Roche/Genentech; Sanofi; Spark Therapeutics; Takeda; uniQure
    Research funding from: Siemens


  • Heather P. Friedman, MPH

    Medical Education Director, Medscape, LLC


    Heather P. Friedman, MPH, has no relevant financial relationships.

Compliance Reviewer

  • Lisa Simani, APRN, MS, ACNP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

Developed through a partnership between Medscape and National Hemophilia Foundation.


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Clinical Quiz: Are You Ready for Hemophilia Gene Therapy?

Authors: Steven W. Pipe, MDFaculty and Disclosures

CME / ABIM MOC Released: 11/3/2022

Valid for credit through: 11/3/2023, 11:59 PM EST


Learning Feedback Questions

Before you begin, please take this brief survey.

  • Print